Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trialChristopher Koh, Theo Heller, Peter A. Pinto et al.|The Lancet Infectious Diseases|2015Cited by 262
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 studyCihan Yurdaydın, Jeffrey S. Glenn, Onur Keskın et al.|Hepatology|2017Cited by 150
PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinomaXiaochao Tan, Jonathan M. Kurie, Priyam Banerjee et al.|Science Translational Medicine|2020Cited by 68
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countriesHomie Razavi, Ching‐Chih Hu, Marı́a Buti et al.|Journal of Hepatology|2023Cited by 61
HDV RNA assays: Performance characteristics, clinical utility, and challengesHeiner Wedemeyer, Mitchell Leus, Thomas R. Battersby et al.|Hepatology|2023Cited by 48